

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/47356189>

# Quantitative Model of the Phase Behavior of Recombinant pH-Responsive Elastin-Like Polypeptides

ARTICLE *in* BIOMACROMOLECULES · OCTOBER 2010

Impact Factor: 5.75 · DOI: 10.1021/bm100571j · Source: PubMed

---

CITATIONS

23

---

READS

15

## 4 AUTHORS, INCLUDING:



[John Andrew Mackay](#)

University of Southern California

49 PUBLICATIONS 3,320 CITATIONS

[SEE PROFILE](#)



[Ashutosh Chilkoti](#)

Duke University

292 PUBLICATIONS 15,056 CITATIONS

[SEE PROFILE](#)

# Quantitative Model of the Phase Behavior of Recombinant pH-Responsive Elastin-Like Polypeptides

J. Andrew MacKay,<sup>†,§</sup> Daniel J. Callahan,<sup>†</sup> Kelly N. FitzGerald,<sup>†,‡</sup> and Ashutosh Chilkoti<sup>\*,†</sup>

Department of Biomedical Engineering, Duke University, 101 Science Drive,  
Durham, North Carolina 27708-0281, United States, St. Jude Medical, 11175 Cicero Drive, Suite 675,  
Alpharetta, Georgia 30022, United States, and Department of Pharmacology and Pharmaceutical  
Sciences, University of Southern California, 1985 Zonal Avenue,  
Los Angeles, California 90033-9121, United States

Received May 26, 2010; Revised Manuscript Received August 30, 2010

Quantitative models are required to engineer biomaterials with environmentally responsive properties. With this goal in mind, we developed a model that describes the pH-dependent phase behavior of a class of stimulus responsive elastin-like polypeptides (ELPs) that undergo reversible phase separation in response to their solution environment. Under isothermal conditions, charged ELPs can undergo phase separation when their charge is neutralized. Optimization of this behavior has been challenging because the pH at which they phase separate,  $pH_t$ , depends on their composition, molecular weight, concentration, and temperature. To address this problem, we developed a quantitative model to describe the phase behavior of charged ELPs that uses the Henderson–Hasselbalch relationship to describe the effect of side-chain ionization on the phase-transition temperature of an ELP. The model was validated with pH-responsive ELPs that contained either acidic (Glu) or basic (His) residues. The phase separation of both ELPs fit this model across a range of pH. These results have important implications for applications of pH-responsive ELPs because they provide a quantitative model for the rational design of pH-responsive polypeptides whose transition can be triggered at a specified pH.

## Introduction

New materials capable of undergoing bioresponsive self-assembly and higher-order supramolecular organization are required to build the next generation of biomaterials. Genetic engineering is a promising approach to synthesize such materials, and guided by this belief, we have been exploring recombinant elastin-like polypeptides (ELPs) as building blocks for self-assembled nanoparticles for drug delivery,<sup>1–3</sup> hydrogels for local drug delivery,<sup>4</sup> and tissue engineering.<sup>5–8</sup> ELPs are recombinant protein–polymers composed of pentapeptide (Val-Pro-Gly-*Xaa*-Gly)<sub>*L*</sub> repeat units and are so named because this pentamer and its analogs are recurring motifs in tropoelastin in a wide range of species.<sup>9</sup> ELPs undergo an inverse phase transition, also called a lower critical solution temperature (LCST) transition, at a characteristic temperature,  $T_i$ , above which they phase separate from bulk water. At the molecular level, the identities of *Xaa* and *L* control this phase behavior.<sup>10</sup> When pH-sensitive acidic or basic amino acids are placed at some of the *Xaa* positions, the  $T_i$  of these ELPs becomes dependent on pH.

Polymers that show LCST behavior are one class of materials that can be used as the building blocks for bioresponsive systems,<sup>11</sup> and we have chosen to focus on ELPs for the following reasons: ELPs are genetically encodable, so they can be produced in heterologous expression systems with high yield and purity. The ability to produce ELPs recombinantly has several important ramifications. First, we have found that ELP fusion proteins also retain stimulus-responsive behavior. The

ability to impart stimulus responsiveness to proteins and peptides by gene-level fusion of an ELP tail is a simple method to create proteins and peptides whose physical behavior (e.g., solubility) can be externally modulated by a small change in solution conditions. This attribute is extraordinarily useful because it generates a range of applications in biotechnology, ranging from nonchromatographic purification of ELP fusions<sup>12–14</sup> to the development of affinity capture reagents<sup>15–17</sup> and interfaces.<sup>18–20</sup> ELPs are also attractive for biomedical applications<sup>21–24</sup> including drug delivery<sup>11,23,25–29</sup> and tissue engineering<sup>5–8</sup> because they are biocompatible,<sup>30,31</sup> nontoxic, and biodegradable.<sup>3,27</sup> For biomedical applications in which ELPs are injected or implanted in vivo, genetically encoded synthesis provides significant advantages over synthetic polymers that display LCST behavior because it provides precise control over their composition, molecular weight (MW), and polydispersity, features that control their in vivo biodistribution, biodegradation, and disposition.<sup>25,32</sup>

In an effort to diversify the range of applications of ELPs, we have recently focused on the use of pH as a trigger of their phase-transition behavior.<sup>33</sup> This effort was motivated by the recognition that pH plays a role in many biological processes and is hence a useful trigger to develop bioresponsive therapeutics. For example, the extravascular space within tumors has a reduced pH compared with that found in blood or many healthy tissues because of tumor hypoxia and production of lactate by anaerobic glycolysis. A large percentage of aggressive clinical tumors display regions with elevated levels of lactic acid,<sup>34</sup> and areas of lactic acid production can be diffusely spread across large regions of the tumor. The elevation in lactic acid level correlates with the lower pH of tumors.<sup>35</sup> There is, however, considerable variability between tumor types; sarcoma and adenocarcinoma have pH values as low as 5.6, squamous

\* Corresponding author. E-mail: chilkoti@duke.edu. Fax: 919-660-5409. Tel: 919-660-5373.

<sup>†</sup> Duke University.

<sup>‡</sup> St. Jude Medical.

<sup>§</sup> University of Southern California.

cell carcinoma have pHs as low as 6.3, and melanoma have been measured as low as pH 6.8.<sup>35</sup>

Because ELPs undergo a sharp phase change that can be isothermally triggered by a small change in pH, and because this pH responsiveness is controlled by the type and number of ionizable residues and MW of the ELP, in principle, it should be possible to synthesize ELPs that are designed to undergo their phase transition within a narrow, physiologically relevant range of pH that is optimized for delivery to a specific tumor type. This level of control of the pH responsiveness of ELPs or other stimulus-responsive polymers requires a biophysical model that is capable of predicting the pH responsiveness of these polymers with great precision. However, to the best of our knowledge, a quantitative model that allows prediction of the pH at which a charged ELP will undergo its phase transition does not exist. In an effort to address this limitation, we report herein a quantitative model that incorporates the effect of pH with MW and solution concentration, the two other primary variables that control the phase-transition behavior of an ELP, to predict quantitatively the  $T_i$  of ionizable ELPs.

## Materials and Methods

**ELP Biosynthesis and Purification.** ELPs were synthesized by heterologous expression of a plasmid-borne synthetic gene in *E. coli*, as previously described (Figure 1 of the Supporting Information).<sup>25</sup> Genes encoding ELPs were constructed using recursive directional ligation (RDL) in pUC19 plasmids grown in TOP10 cells (Invitrogen, Carlsbad, CA) and then transferred to modified pET25b+ expression vectors (Novagen, Madison, WI). We purchased 5'-phosphorylated oligonucleotides from Integrated DNA Technologies (Coralville, IA). All DNA plasmids were purified using Qiaprep spin miniprep kits (Qiagen, Germantown, MD). To generate the acidic ELPs containing glutamic acid guest residues (Glu), we prepared an annealed oligonucleotide cassette from a sense 99-base oligonucleotide (5'-AATTCATATGGGCCACGGCGTGGGCGTTCCGGGTATCGGTGTTCCGGGTATCGGTGTTCCGGGTGAAGGTGTTCCGGGTATCGGTGTGCCGGGCTGGCA-3') and an antisense 99-base oligonucleotide (5'-AGCTTGCCAGCCCGGCACACCGATACCCGGAACACCTTCACCCGAACACCGATACCCGGAACACCGATACCCGACGCCACCGCGTGGCCCATATG-3'). To generate basic ELPs containing histidine (His) guest residues, an annealed oligonucleotide cassette was prepared from a sense 99-base oligonucleotide (5'-AATTCATATGGGCCACGGCGTGGGCGTTCCGGGCCACGGGTGTTCCAGGTGGCGGCGTACCGGGCCACGGTGTCTCGGTGCTGGCGTGCCGGGCTGGCA-3') and an antisense 99-base oligonucleotide (5'-TGCCAGCCCGGCACGCCAGCACCAGGAACACCGTGGCCCCGTACGCCGCCACCTGGGACACCGTGGCCCCGAACACCCACGCCGTGGCCCCATATGAATT-3'). For each ELP, the pUC19 vector was digested with *EcoRI* and *HindIII* (New England Biolabs, Ipswich, MA), and the digest was purified using a QIAquick PCR purification kit (Qiagen, Germantown, MD). The vector and annealed oligonucleotide cassette were ligated using T4 DNA ligase (Invitrogen, Carlsbad, CA), transformed into chemically competent cells, and selected on Terrific Broth (TB) agar plates with ampicillin (100  $\mu$ g/mL). Colonies were screened by diagnostic digestion, and positive clones were confirmed by DNA sequencing. To oligomerize the "monomer" gene of each ELP to create a library of genes that span the MW range of interest, RDL was carried out as previously described.<sup>25</sup> In a typical round of RDL, linear inserts were generated by restriction digestion of plasmid DNA with *PflmI* and *BglII*, and the correct insert was purified by gel extraction. The linearized vector was generated by incubation with *PflmI*; the linearized vector was dephosphorylated using calf intestinal phosphatase (CIP) and then purified using a PCR purification kit. The linearized vector and insert were then ligated to obtain successively longer synthetic genes. After the desired number of rounds of RDL to oligomerize the monomer gene to the desired number of repeats, the insert gene was

obtained by restriction digestion, as described above, and ligated into a modified pET25b+ expression vector that was linearized by digestion with *SfiI*.<sup>25</sup> This approach produced synthetic genes (Table 1 of the Supporting Information) that express acidic ELPs with the sequence MSKGGP[XGVPG]<sub>L=40,80,160</sub>WPC with X = V/I/E [1:3:1] and basic ELPs with the sequence MSKGGP[XGVPG]<sub>L=40,60,100,120</sub>WP with the ratio of X = V/H/G/A [1:2:1:1]. Successful ligation products were transformed into chemically competent BLR(DE3) (Novagen, Madison, WI) cells for ELP expression.


To express ELPs, 1 L cultures of TB (MoBio; Carlsbad, CA) were seeded from 50 mL of overnight cultures (100  $\mu$ g/mL ampicillin) and incubated for 24 h at 37 °C and ~210 rpm. Bacterial cultures were centrifuged, resuspended in ~20 mL of PBS, and disrupted by probe ultrasonication (Misonix, Farmingdale, NY). To precipitate DNA with the insoluble debris, the lysate was supplemented with polyethyleneimine to a concentration of ~1% and centrifuged at 16 100 RCF at 4 °C. The clarified supernatant was removed, supplemented with up to 3 M NaCl, as required to induce the ELP transition, and purified by inverse transition cycling (ITC).<sup>9,12</sup> In brief, ITC consists of raising the NaCl concentration as needed (0 to 3 M) to induce ELP phase separation. The ELP pellet was collected by hot centrifugation at 16 100 RCF (37 °C). The enriched pellet was resuspended in buffer and centrifuged in the cold (4 °C) to remove aggregated contaminants. The enriched ELP solution was subjected to this cycle of hot and cold centrifugation four to six times until sufficient purity was obtained. ELP purity was confirmed using SDS-PAGE (Figure 2 of the Supporting Information). The ELP concentration was determined using UV-vis spectrophotometry and an estimated molar extinction coefficient for the sole tryptophan<sup>36</sup> in each ELP of 5690 cm<sup>-1</sup> M<sup>-1</sup> at 280 nm. Yields of purified ELP were ~100 mg/L culture.

To determine the pH-dependent transition temperature, concentrated ELPs were dialyzed into buffer solutions containing pH-adjusted solutions of sodium succinate (pH < 6.4) or sodium phosphate (pH  $\geq$  6.4). Both buffers were selected on the basis of the relative insensitivity of their  $pK_a$  to temperature. For the acidic ELPs, buffers were prepared with 10 mM buffer and 140 mM NaCl. The basic ELPs were prepared with 100 mM buffer and 50 mM NaCl because they have a higher linear charge density than the acidic ELPs and hence required additional buffering capacity to maintain their pH. We determined ELP transition temperatures on a CARY 300Bio UV-vis spectrophotometer (Varian, Palo Alto, CA) by scanning the temperature at 1 °C/min. The transition temperature was defined as the solution temperature that corresponded to the maximum first derivative of the optical density at 350 nm (Figure 3 of the Supporting Information).

## Results

**pH Dependence of the ELP Phase Transition.** We synthesized two ELP libraries with a range of MWs that have pH-sensitive phase behavior. The first library comprises acidic ELPs that contain multiple glutamic acid residues that repeat along the ELP sequence. Above their  $pK_a$ , these ELPs are charged and have a high phase-transition temperature, but a decrease in pH below their  $pK_a$  leads their glutamic acid residues to be protonated and become neutral, which dramatically reduces their phase-transition temperature. The second library contains the basic amino acid histidine interspersed periodically along the ELP sequence. At low pH, these basic ELPs are charged and soluble; however, when the pH rises above their  $pK_a$ , they become neutralized, and their phase-transition temperatures decrease. Therefore, these two ELP libraries exhibit opposing pH-dependent phase-transition behavior across a range of pH (Figure 1). These pH-triggered ELPs exhibit a phase transition over a wide range of pH that was deliberately chosen to test the robustness of a quantitative model.

As has been previously reported, the phase-transition temperature for nonionic ELPs strongly depends on both the ELP



**Figure 1.** pH and concentration dependence of ELP phase behavior. ELP transition temperatures are plotted as a function of the logarithm of the polymer concentration. For each pH, a best-fit line to eq 7 is presented (Table 1). (a) Acidic ELP of 160 pentamers containing guest residues V/I/E [1:3:1] with a  $pK_a$  of 5.29. (b) Basic ELP of 120 pentamers containing guest residues V/H/G/A [1:2:1:1] with a  $pK_a$  of 6.22.

chain length and its solution concentration,<sup>32</sup> so that these orthogonal variables allow the phase-transition temperature to be finely tuned. We observed that this relationship also holds upon introducing pH-sensitive guest residues to an ELP but that the effect of the pH on the phase-transition temperature dominates over the ELP chain length or its solution concentration. To describe this finding within a quantitative framework, we developed an empirical analytical model that fit the observed pH dependence of the transition temperature ( $T_t$ , in degrees Celsius) of the ELP phase transition of both ELP libraries as a function of their concentration ( $C$ , in micrometers) and length ( $L$ , in pentamers). This model explicitly accommodates the pH-dependent behavior of both the acidic and basic ELP libraries. A key assumption of this model is that the transition temperature at an intermediate pH can be linearly interpolated between the transition temperature of a fully deprotonated ELP at a high pH,  $T_{depro}$ , and a fully protonated ELP at a low pH,  $T_{pro}$ , as follows

$$T_t = f_{depro} T_{depro} + (1 - f_{depro}) T_{pro} \quad (1)$$

where  $f_{depro}$  is the fraction of total ELP guest residues that is deprotonated. This linear approximation is strongly supported by previous observations, which showed that the transition temperature depends linearly on the mixture of both charged and neutral guest residues.<sup>9</sup>

To determine  $f_{depro}$ , the Henderson–Hasselbalch equation can be used to estimate the relative concentration of protonated,  $C_{pro}$ , versus deprotonated,  $C_{depro}$ , guest residues in a polymer solution as follows

$$pH = pK_a + \log \left[ \frac{C_{depro}}{C_{pro}} \right] \quad (2)$$

By conservation of total ionizable residues,  $C_{total}$

$$C_{total} = C_{depro} + C_{pro} \quad (3)$$

Substituting eq 3 into eq 2 and rearranging provides an expression for the fraction of guest residues protonated in the ELP polymer solution.

$$f_{depro} = \frac{C_{depro}}{C_{total}} = \frac{1}{1 + 10^{(pK_a - pH)}} \quad (4)$$

By substituting eq 4 into eq 1 and rearranging, the following approximation is obtained

$$T_t = T_{pro} + \frac{T_{depro} - T_{pro}}{1 + 10^{(pK_a - pH)}} \quad (5)$$

The above equation linearly interpolates between the transition temperature of a fully protonated and a fully deprotonated ELP as a function of pH and was explored in combination with other variables that influence the transition temperature. Note that eq 5 is valid for fitting the behavior of ELPs with either acidic or basic guest residues. Basic amino acids such as histidine are charged in their protonated form; therefore, their transition temperatures decrease above their  $pK_a$ . In contrast, acidic amino acids such as glutamic acid are neutral in their protonated state; therefore, their transition temperatures increase above their  $pK_a$ . Therefore, eq 5 describes the pH-dependent phase-transition behavior of both basic and acidic ELPs.

**$T_t$  Dependence on Concentration at Fixed Length.** Prior to developing a single multivariate model that relates transition temperature to pH, length, and concentration, we first verified that eq 5 is valid at fixed length; furthermore, this step was necessary to confirm our assumption that the  $pK_a$  is roughly independent of the ELP length. Empirical observation has shown that the ELP transition temperature depends on the natural logarithm of the polymer concentration; furthermore, the degree of this dependence is strongly influenced by the selection of guest residues and polymer length.<sup>32</sup> The following relationship has been previously derived to quantify the concentration dependence for ELPs<sup>32</sup>

$$T_t = T^{ref} - b \ln[C] \quad (6)$$

where  $T^{ref}$  is the transition temperature at a reference concentration (1  $\mu$ M here) and ELP concentration,  $C$ , is in units of mM. The slope,  $b$ , represents the concentration dependence of the transition temperature. When eq 6 is written for the protonated ( $T_{pro}^{ref}$ ,  $b_{pro}$ ) and deprotonated ( $T_{depro}^{ref}$ ,  $b_{depro}$ ) forms of the ELP and inserted into eq 5, the following relationship is obtained

$$T_t = T_{pro}^{ref} - b_{pro} \ln[C] + \frac{T_{depro}^{ref} - T_{pro}^{ref} - (b_{depro} - b_{pro}) \ln[C]}{1 + 10^{(pK_a - pH)}} \quad (7)$$


The above equation was used to fit each ELP analyzed in our data set (Figure 1) to obtain the best-fit parameters (Table 1). Interestingly, these data suggest that all parameters of eq



**Table 1.** Dependence of the Transition Temperature on pH and Concentration for ELPs with Fixed Lengths and Guest Residues<sup>a</sup>

ELP guest residues	length, <i>L</i> (pentamers)	p <i>K</i> <sub>a</sub>	<i>T</i> <sub>pro</sub> <sup>ref</sup> (°C)	<i>T</i> <sub>depro</sub> <sup>ref</sup> (°C)	<i>b</i> <sub>pro</sub> (°C/Ln [μM])	<i>b</i> <sub>depro</sub> (°C/Ln [μM])	R <sup>2</sup>	<i>n</i>
V/I/E [1:3:1] <sup>b</sup>	40	5.50 (0.05)	35.2 (1.8)	148 (11)	2.48 (0.53)	15.5 (2.4)	0.990	21
	80	5.51 (0.05)	21.6 (2.3)	81.0 (2.0)	0.42 (0.67)	5.04 (0.54)	0.985	36
	160	5.29 (0.03)	18.6 (1.1)	73.9 (0.8)	0.28 (0.32)	5.09 (0.23)	0.997	30
V/H/G/A [1:2:1:1] <sup>c</sup>	40	6.59 (0.09)	137 (12)	103 (4)	8.4 (2.0)	11.8 (0.9)	0.979	20
	60	6.26 (0.06)	116 (6.7)	62.1 (2.8)	4.3 (1.1)	6.3 (0.6)	0.978	33
	100	6.25 (0.05)	98.0 (4.6)	38.5 (2.9)	2.9 (1.0)	3.1 (0.7)	0.982	30
	120	6.22 (0.05)	95.1 (4.4)	33.4 (2.8)	2.6 (1.0)	2.8 (0.7)	0.985	30

<sup>a</sup> Data fit to eq 7 and parameters reported as the estimate (standard error). <sup>b</sup> Acidic ELP at pH 2.5–7.8, and concentrations from 5 to 100 μM. <sup>c</sup> Basic ELP at pH 5.5–8.0, and concentrations from 10 to 500 μM.



**Figure 2.** Length and concentration dependence of ELP phase behavior. For each length, a best-fit line to eq 8 is presented (Table 2). (a) Acidic ELP library at pH 4.6 containing guest residues V/I/E [1:3:1]. (b) Basic ELP library at pH 8.0 containing guest residues V/H/G/A [1:2:1:1].

7 depend on length except for the p*K*<sub>a</sub>. The observation that the p*K*<sub>a</sub> of an ionizable ELP is independent of its chain length leads us to propose the assumption that the p*K*<sub>a</sub> of an ELP is constant within its compositional library.

***T*<sub>t</sub> Dependence on Concentration and Length at Fixed pH.** Having demonstrated that the ELP phase-transition temperature can be modeled by the Henderson–Hasselbalch equation (Figure 1), we next investigated the dependence of ELP chain length and its solution concentration at a fixed pH. ELP transition temperatures depend on the polymer MW, related here to the number of pentameric repeats, *L* (Figure 2). For an ELP library at constant pH, the dependence of the transition temperature on concentration and length was expected to follow the empirical relationship previously developed by Meyer and Chilkoti<sup>32</sup>

$$T_t = T_c + \frac{k}{L} \ln \left[ \frac{C_c}{C} \right] \quad (8)$$

where *T*<sub>c</sub> is a critical transition temperature described by the extrapolated intersection of the concentration-dependent transition temperatures from ELPs of different lengths, *L*. These curves intersect at a critical concentration, *C*<sub>c</sub>; furthermore, an interaction parameter *k* is included to modulate the dependence

of *T*<sub>t</sub> on length and concentration. To verify that both acidic and basic ELPs follow this principle, we fit both libraries to eq 8 at a number of fixed pH values (Table 2). The fit parameters demonstrate that *T*<sub>c</sub> and *k* both depend on pH; however, *C*<sub>c</sub> does not substantially change with pH. This is partially due to the fact that *C*<sub>c</sub> is an extrapolated value, far above the concentration that is achievable in a dilute, buffered solution. Despite this, it appears that at constant pH, eq 8 accurately describes the transition behavior of both acidic and basic ELPs (Figure 2).

***T*<sub>t</sub> Codependence on Concentration, Length, and pH.** Having demonstrated that the ELP phase behavior is simultaneously pH-, length-, and concentration-dependent, it is now possible to develop a single equation that accounts for each of these behaviors. To do this, a form of eq 8 that represents both the protonated and deprotonated ELP can be substituted into eq 5 and rearranged, yielding

$$T_t = T_{c,pro} + \frac{k_{pro}}{L} \ln \left[ \frac{C_{c,pro}}{C} \right] + \frac{T_{c,depro} - T_{c,pro} + \frac{1}{L} \left( k_{depro} \ln \left[ \frac{C_{c,depro}}{C} \right] - k_{pro} \ln \left[ \frac{C_{c,pro}}{C} \right] \right)}{1 + 10^{(pK_a - pH)}} \quad (9)$$

where *C*<sub>c,depro</sub> and *C*<sub>c,pro</sub> are the critical concentrations for the deprotonated and protonated polymers, respectively, *T*<sub>c,depro</sub> and *T*<sub>c,pro</sub> are the critical transition temperatures for the deprotonated and protonated polymers, respectively, and *k*<sub>depro</sub> and *k*<sub>pro</sub> are the parameters for the length–concentration interaction for the deprotonated and protonated polymers, respectively. Equation 9 assumes that p*K*<sub>a</sub> is independent of concentration and length, as supported by Table 1. Including p*K*<sub>a</sub>, eq 9 has seven parameters, so some simplification of this equation was considered to be desirable. The critical concentration, *C*<sub>c</sub>, is an extrapolated value, and it does not appear to have a significant dependence on pH (Table 2). Therefore, we simplified eq 9 by assuming that the critical concentrations are roughly equal between the protonated and deprotonated forms. After substitution of *C*<sub>c,pro</sub> and *C*<sub>c,depro</sub> with *C*<sub>c</sub> into eq 9, we obtain

$$T_t = T_{c,pro} + \frac{k_{pro}}{L} \ln \left[ \frac{C_c}{C} \right] + \frac{T_{c,depro} - T_{c,pro} + \frac{(k_{depro} - k_{pro})}{L} \left( \ln \left[ \frac{C_c}{C} \right] \right)}{1 + 10^{(pK_a - pH)}} \quad (10)$$

The above relationship was fit to both the acidic and basic ELP libraries, spanning a range of concentration, *C*, polymer length, *L*, and pH to determine the six parameters (Table 3). These parameters have been used to fit data as a function of

**Table 2.** Dependence of the Transition Temperature on Length and Concentration at Fixed pH<sup>a</sup>


ELP guest residues	pH	$T_c$ (°C)	$K$ (°C pentamers)	$C_c$ (mM)	$R^2$	$n$
V/I/E [1:3:1] <sup>b</sup>	6.5	39.5 (2.7)	363 (72)	3.1 (2.7)	0.786	22
	5.5	32.8 (2.5)	278 (80)	1.8 (2.2)	0.841	14
	4.6	19.7 (1.0)	126 (27)	5.4 (6.7)	0.927	15
	3.7	13.3 (0.9)	106 (23)	7.8 (10.5)	0.929	15
V/H/G/A [1:2:1:1] <sup>c</sup>	8.0	3.6 (1.2)	394 (24)	10.9 (3.4)	0.978	21
	7.4	8.5 (1.5)	403 (29)	9.9 (3.6)	0.968	21
	6.8	20.5 (1.2)	354 (26)	16.5 (6.0)	0.972	20
	6.4	30.9 (1.4)	348 (29)	20.9 (8.3)	0.964	19
	6.0	39.9 (1.5)	308 (31)	42.0 (22.7)	0.958	19
	5.5	58.7 (1.4)	340 (30)	24.8 (9.8)	0.958	13

<sup>a</sup> Data fit to eq 8 and parameters reported as the estimate (standard error). <sup>b</sup> Acidic ELP lengths from 40 to 160 pentamers and concentrations from 5 to 100  $\mu$ M. <sup>c</sup> Basic ELP lengths from 40 to 120 pentamers and concentrations from 10 to 500  $\mu$ M.

**Table 3.** Multiple Nonlinear Regression Parameters Describing the Dependence of the Transition Temperature on pH, Length, and Concentration<sup>a</sup>

ELP guest residues	$pK_a$	$T_{c,pro}$ (°C)	$T_{c,depro}$ (°C)	$k_{pro}$ (°C pentamers)	$k_{depro}$ (°C pentamers)	$C_c$ (mM)	$R^2$	$n$
V/I/E [1:3:1] <sup>b</sup>	5.36 (0.04)	14.7 (1.2)	46.1 (1.2)	118 (17)	398 (42)	1.4 (0.5)	0.97	87
V/H/G/A [1:2:1:1] <sup>c</sup>	6.28 (0.03)	68.4 (2.1)	3.1 (1.2)	309 (32)	376 (18)	16.1 (3.7)	0.98	113

<sup>a</sup> Data fit to eq 10 and parameters reported as estimate (standard error). <sup>b</sup> Acidic ELP lengths from 40 to 160 pentamers, pH 2.5–7.8, and concentrations from 5 to 100  $\mu$ M. <sup>c</sup> Basic ELP lengths from 40 to 120 pentamers, pH 5.5–8.0, and concentrations from 10 to 500  $\mu$ M.




**Figure 3.** pH dependence of the ELP phase behavior. ELP transition temperatures plotted as a function of pH. For each ELP chain length, a best-fit curve following eq 10 has been indicated (Table 3). (a,b) Acidic ELP library containing guest residues V/I/E [1:3:1]. (a) Transition temperatures as a function of pH at 100  $\mu$ M. (b) Predicted versus observed transition temperatures for global fit ( $R^2 = 0.98$ ,  $n = 87$ ). (c,d) Basic ELP library containing guest residues V/H/G/A [1:2:1:1]. (c) Transition temperatures as a function of pH at 100  $\mu$ M. (d) Predicted versus observed transition temperatures for global fit ( $R^2 = 0.98$ ,  $n = 113$ ).

pH (Figure 3). Impressively, the global model fit describes ~97% of the observed variability in the transition temperature for both libraries.

**Development of an Isothermal ELP Phase Diagram.** Some of the most interesting applications for pH-responsive ELPs are to develop smart biomaterials that respond to physiologically relevant pH gradients. Therefore, we note that a rearrangement of eq 10 can be used to estimate the isothermal transition  $pH_t$  at which these ELPs undergo their phase transition as a function of ELP concentration and chain length. The following rearrangement of eq 10 is solved for the inverse phase-transition pH,  $pH_t$ .

$$pH_t = pK_a + \log \left[ \frac{T - T_{c,pro} - \frac{k_{pro}}{L} \ln \left[ \frac{C_c}{C} \right]}{T_{c,depro} - T + \frac{k_{depro}}{L} \ln \left[ \frac{C_c}{C} \right]} \right] \quad (11)$$

ELP chain length and concentration are simple to control; furthermore, the data presented in Table 3 can be used to select optimal conditions to optimize  $pH_t$  within several pH units of the observed  $pK_a$  (acidic:  $pK_a = 5.36$ ; basic  $pK_a = 6.28$ ). By plugging in the best-fit parameters obtained in Table 3, eq 11 can be used to estimate the pH at which a given ELP may transition at body temperature (Figure 4).



**Figure 4.** Transition pH isotherms for acidic and basic ELPs. Isothermal transition  $pH_i$  have been calculated for ELPs at a constant temperature of 37 °C for a variety of accessible lengths and concentrations (eq 11; Table 3). This phase diagram permits selection of a suitable length and concentration for achieving a transition at the target pH. (a) Predicted library of acidic ELPs containing guest residues V/I/E [1:3:1], which are water-soluble above the indicated boundaries. (b) Predicted library of basic ELPs containing guest residues V/H/G/A [1:2:1:1], which are soluble below the indicated boundaries.

The above relationship permits the selection of the best length and mixture of guest residues to trigger either the aggregation or the disaggregation of ELP at physiologically relevant pH. For example, acidic ELPs may remain soluble in the blood but aggregate when they encounter the low pH in the extracellular tumor fraction or some intracellular compartments. Such a polymer could be useful to induce local retention of bulk aggregates, or polypeptide block copolymers could be designed that form multivalent micelles. The 60 pentamer acidic ELP depicted in Figure 4a is perfectly tuned to drive the assembly of aggregates in intracellular compartments because they are highly soluble at pH 7.4 but have a  $pH_i$  of 5.5 (at 100  $\mu\text{M}$ ). To target the extracellular tumor pH, a phase diagram like Figure 4 could be used to guide the design of new mixtures of guest residues that have a higher  $pH_i$ .

In contrast, block copolymers that contain the basic ELP are well-suited to engineer multivalent micelles that remain assembled in the blood at pH 7.4. Basic ELPs can serve as the hydrophobic components of block copolymers designed to disassemble and release their cargo in response to the stimulus of either low extracellular pH, improving the interstitial penetration of the released drug, or endosomal pH, potentially leading to endosomal disruption for intracellular drug release. Taking 100  $\mu\text{M}$  as an approximation of the ELP concentration, the phase diagram constructed in Figure 4b suggests that a micelle core segment of roughly 80 pentamers has a  $pH_i$  of 7.0, which would disaggregate between pH 7.4 and the tumor extracellular pH 6.8. Alternatively, a basic ELP with a different mixture of guest residues might be used to target micelle disruption to the endosomal pH 5.0. Therefore, these phase diagrams will allow us to tailor the design of new polypeptide biomaterials with optimal physiological response.

We successfully developed two novel libraries of ELPs that phase separate near physiological temperature and pH; furthermore, one library (histidine) is soluble only at acidic pH, and the other (glutamic acid) is soluble only at basic pH. These amino acids were selected because they have titratable chemistries and  $pK_a$  values within the physiologically relevant range. When the amino acids become either cationic or anionic, the phase-transition temperature and solubility are increased. Histidine becomes protonated under acidic conditions, producing a cationic ELP with high solubility. In contrast, glutamic acid becomes deprotonated under basic conditions, conferring an anionic charge and enhancing ELP solubility. Lysine, aspartic acid, and tyrosine also have titratable chemistries, which may be useful to target phenomena that occur at pH values near their  $pK_a$  values. Presumably, lysine-containing ELPs would behave qualitatively similarly to histidine-containing ELPs, albeit at a much higher pH. In contrast, aspartic acid and tyrosine guest residues are expected to behave qualitatively similarly to the glutamic-acid-containing ELPs. Glutamic acid and histidine were chosen as the ionizable residues of interest because their  $pK_a$  values (4.3 and 6.1, respectively) are closest to the physiologically relevant range. The high  $pK_a$  values of tyrosine and lysine (10 and 10.5, respectively) place those responses outside of the relevant range, and while the  $pK_a$  of aspartic acid is similar to that of glutamic acid, the uncharged aspartic acid is less hydrophobic, meaning that protonation of this residue under acidic conditions would have less of an effect on the ELP  $T_i$ . Even though they have opposite responses to pH, our proposed model perfectly describes the behavior of both acidic and basic ELPs. Variations on this model may be applicable to other biopolymer phase transitions that depend on concentration or MW. Many other polypeptide assembly mechanisms depend on ionizable amino acids.<sup>37</sup> For example, leucine zipper assemblies are pH-dependent because they are partially stabilized by electrostatic interactions between titratable amino acid side chains. These models may enable precise engineering of recombinant biopolymers that assemble at target physiological pH and temperature.

## Conclusions

Herein we have described two libraries of ELPs with basic or acidic guest residues that have pH-responsive phase behavior. We observed that their concentration and MW influence their phase-transition behavior and then developed an empirical model that describes the ELP phase-transition temperature as a function of concentration, chain length, and pH. This approach is valid for ELPs that undergo phase separation at high pH (histidine-containing ELPs) and low pH (glutamic acid-containing ELPs). These results are useful because they will enable the rational design of ELPs that are capable of exhibiting phase-transition behavior in response to a specified change in pH as the trigger. Future work will examine the generality of this model with respect to ELPs that contain other ionizable residues not used to develop the model (e.g., Asp, Lys) as well as the validity of this model in predicting the pH-triggered self-assembly of di-block ELPs that contain one ionizable block, with the goal of rational design of ELPs that exhibit self-assembly into nanoscale structures such as micelles or vesicles or conversely exhibit pH-triggered disassembly in response to pH gradients that exist in physiological systems.

**Acknowledgment.** This work was supported with NIH grant F32-CA-123889 to J.A.M. and NIH grants R01-GM-061232 and R01-EB-000188 to A.C.

**Supporting Information Available.** Additional characterization of the polymers analyzed within this manuscript. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## References and Notes

- (1) Dreher, M. R.; Simnick, A. J.; Fischer, K.; Smith, R. J.; Patel, A.; Schmidt, M.; Chilkoti, A. *J. Am. Chem. Soc.* **2008**, *130*, 687–694.
- (2) Meyer, D. E.; Kong, G. A.; Dewhirst, M. W.; Zalutsky, M. R.; Chilkoti, A. *Cancer Res.* **2001**, *61*, 1548–1554.
- (3) MacKay, J. A.; Chen, M.; McDaniel, J. R.; Liu, W.; Simnick, A. J.; Chilkoti, A. *Nat. Mater.* **2009**, *8*, 993–999.
- (4) Liu, W.; Mackay, J. A.; Dreher, M. R.; Chen, M.; McDaniel, J. R.; Simnick, A. J.; Callahan, D. J.; Zalutsky, M. R.; Chilkoti, A. *J. Controlled Release* **2010**, *144*, 2–9.
- (5) McHale, M. K.; Setton, L. A.; Chilkoti, A. *Tissue Eng.* **2005**, *11*, 1768–1779.
- (6) Betre, H.; Ong, S. R.; Guilak, F.; Chilkoti, A.; Fermor, B.; Setton, L. A. *Biomaterials* **2006**, *27*, 91–99.
- (7) Lim, D. W.; Nettles, D. L.; Setton, L. A.; Chilkoti, A. *Biomacromolecules* **2008**, *9*, 222–230.
- (8) Shamji, M. F.; Whitlatch, L.; Friedman, A. H.; Richardson, W. J.; Chilkoti, A.; Setton, L. A. *Spine (Philadelphia)* **2008**, *33*, 748–754.
- (9) Urry, D. W. *J. Phys. Chem. B* **1997**, *101*, 11007–11028.
- (10) Yamaoka, T.; Tamura, T.; Seto, Y.; Tada, T.; Kunugi, S.; Tirrell, D. A. *Biomacromolecules* **2003**, *4*, 1680–1685.
- (11) Dreher, M. R.; Liu, W.; Michelich, C. R.; Dewhirst, M. W.; Chilkoti, A. *Cancer Res.* **2007**, *67*, 4418–4424.
- (12) Meyer, D. E.; Chilkoti, A. *Nat. Biotechnol.* **1999**, *17*, 1112–1115.
- (13) Chilkoti, A.; Christensen, T.; MacKay, J. A. *Curr. Opin. Chem. Biol.* **2006**, *10*, 652–657.
- (14) Lim, D. W.; Trabbic-Carlson, K.; Mackay, J. A.; Chilkoti, A. *Biomacromolecules* **2007**, *8*, 1417–1424.
- (15) Megeed, Z.; Winters, R. M.; Yarmush, M. L. *Biomacromolecules* **2006**, *7*, 999–1004.
- (16) Christensen, T.; Trabbic-Carlson, K.; Liu, W.; Chilkoti, A. *Anal. Biochem.* **2007**, *360*, 166–168.
- (17) Ge, X.; Filipe, C. D. *Biomacromolecules* **2006**, *7*, 2475–2478.
- (18) Xu, F.; Joon, H. M.; Trabbic-Carlson, K.; Chilkoti, A.; Knoll, W. *Biointerphases* **2008**, *3*, 66–74.
- (19) Nath, N.; Chilkoti, A. *Anal. Chem.* **2003**, *75*, 709–715.
- (20) Nath, N.; Chilkoti, A. *J. Am. Chem. Soc.* **2001**, *123*, 8197–8202.
- (21) Lim, D. W.; Nettles, D. L.; Setton, L. A.; Chilkoti, A. *Biomacromolecules* **2007**, *8*, 1463–1470.
- (22) Wright, E. R.; Conticello, V. P. *Adv. Drug Delivery Rev.* **2002**, *54*, 1057–1073.
- (23) Rincon, A. C.; Molina-Martinez, I. T.; de Las Heras, B.; Alonso, M.; Bailez, C.; Rodriguez-Cabello, J. C.; Herrero-Vanrell, R. *J. Biomed. Mater. Res., Part A* **2006**, *78A*, 343–351.
- (24) Mart, R. J.; Osborne, R. D.; Stevens, M. M.; Ulijn, R. V. *Soft Matter* **2006**, *2*, 822–835.
- (25) Chilkoti, A.; Dreher, M. R.; Meyer, D. E. *Adv. Drug Delivery Rev.* **2002**, *54*, 1093–111.
- (26) Chilkoti, A.; Dreher, M. R.; Meyer, D. E.; Raucher, D. *Adv. Drug Delivery Rev.* **2002**, *54*, 613–630.
- (27) Liu, W.; Dreher, M. R.; Furgeson, D. Y.; Peixoto, K. V.; Yuan, H.; Zalutsky, M. R.; Chilkoti, A. *J. Controlled Release* **2006**, *116*, 170–8.
- (28) Bae, Y.; Buresh, R. A.; Williamson, T. P.; Chen, T. H. H.; Furgeson, D. Y. *J. Controlled Release* **2007**, *122*, 16–23.
- (29) Massodi, I.; Bidwell, G. L.; Raucher, D. *J. Controlled Release* **2005**, *108*, 396–408.
- (30) Megeed, Z.; Cappello, J.; Ghandehari, H. *Adv. Drug Delivery Rev.* **2002**, *54*, 1075–1091.
- (31) Urry, D. W.; Parker, T. M.; Reid, M. C.; Gowda, D. C. *J. Bioact. Compat. Polym.* **1991**, *6*, 263–282.
- (32) Meyer, D. E.; Chilkoti, A. *Biomacromolecules* **2004**, *5*, 846–851.
- (33) Wu, Y.; MacKay, J. A.; McDaniel, J. R.; Chilkoti, A.; Clark, R. L. *Biomacromolecules* **2009**, *10*, 19–24.
- (34) Schroeder, T.; Yuan, H.; Viglianti, B. L.; Peltz, C.; Asopa, S.; Vujaskovic, Z.; Dewhirst, M. W. *Cancer Res.* **2005**, *65*, 5163–5171.
- (35) Maseide, K.; Kalliomaki, T.; Hill, R. P. *Microenvironmental Effects on Tumour Progression and Metastasis. In Integration/Interaction of Oncologic Growth*; Meadows, G. G., Ed.; Cancer Growth and Progression Series 15; Springer: Dordrecht, The Netherlands, 2005; pp 1–29.
- (36) Pace, C. N.; Vajdos, F.; Fee, L.; Grimsley, G.; Gray, T. *Protein Sci.* **1995**, *4*, 2411–2423.
- (37) Mackay, J. A.; Chilkoti, A. *Int. J. Hyperthermia* **2008**, *24*, 483–495.

BM100571J